LONDON, September 21, 2017 /PRNewswire/ --
Twenty years ago, it was vilified as a 'gateway drug'. Now, cannabis has grown into a big business, with the potential to become even bigger as laws are scheduled to change to reflect shifting social attitudes towards marijuana and investment picks up to take advantage of increased demand.
And make no mistake: the demand is huge. In the United States, the legal cannabis industry is worth $6.7 billion, according to Bloomberg. Actively watching the industry include: Altria Group (NYSE: MO), Insys Therapeutics (NASDAQ: INSY), GW Pharmaceuticals (NASDAQ: GWPH), Teva Pharmaceuticals (NYSE:TEVA), MedReleaf Corp (OTC: MEDFF) (TSX: LEAF.TO)
In Canada alone, cannabis is estimated to reach an $8 billion market with 150,000 people using marijuana for medical purposes. Yet estimates indicate that number could increase dramatically after pot is legalized next year: by 2021 there could be 3.6 million legal users consuming 420,000 kilograms of pot.
With the legal cannabis industry still in its infancy, the potential for growth is huge. At the moment, legal growers supply only 31,000 kilograms of Canada's weed, or 5 percent of anticipated total medical and recreational demand. To avoid bottlenecks and keep supply coming, Canada's pot-growing business must take off, and fast. Dozens of underground producers, who have grown illegally for years, could start supplying existing demand within a few years, if they can obtain licenses and build infrastructure.
Cannabis is virtually unique: an emerging sector tainted for years by high-risk and regulatory uncertainty, it has yet to be penetrated by tier-one capital, as institutional investors have stayed away.
Investing in cannabis can be tricky. Publicly-traded companies are scarce, most are small-cap and penny stocks, and finding those with strong prospects for growth can be challenging. The amount invested globally into cannabis ventures remains relatively small, only $220 million in 2016. Yet that's a significant increase from investment in 2013, which was a scant $13 million.
But the opportunities for smaller investors to get in the ground floor are significant, especially when you look at what some newer firms are bringing to the table and the likelihood that larger firms, particularly those in the tobacco trade, will get in on the action as well.
Here's a look at some companies that are getting into the cannabis game:
It makes sense for a major tobacco company to be interested in cannabis. Back in the 1960s, when social interest in marijuana began to grow, rumors circulated that Big Tobacco was buying up brand names for marijuana products while considering investments in cannabis production.
A crackdown on drug use and a pushback against marijuana quashed that attempt, but with the norms changing, a few of Big Tobacco's most prominent members are re-evaluating their interest in cannabis.
A major reason is the declining sales of cigarettes. For the last several decades Big Tobacco have focused on emerging markets as smoking faded in the developed world. But marijuana represents a lucrative new market, one which is attracting new attention from the larger tobacco firms, albeit in a slow, hesitant fashion.
With the regulatory situation in the United States and elsewhere still uncertain, larger firms are wary of investing too much in a sector which could remain constrained.
Philip Morris is no exception. In 2016 the company pumped $20 million into Syqe Medical, an Israeli firm developing new technology for inhaling medical marijuana, the second-largest cannabis deal of 2016. Rumors circulated in 2016 that the company was about to introduce a weed cigarette, but the news proved false.
The company has been exploring reduced-risk smoking products, with its heated-tobacco iQOS system currently under consideration by the US Food and Drug Administration as a 'modified risk tobacco product'. It isn't much of a stretch to see the company moving from this technology to similar tech that focuses on medical marijuana.
While additional signs from the tobacco firm regarding interest in marijuana have been sketchy, smart speculation would point to a growing interest to take advantage of marijuana use. Despite its initial hesitation, it seems likely that Philip Morris will attempt to become more involved in cannabis in the future.
Canada looks like the next big frontier in marijuana plays. The country is looking at full legalization on July 1, 2018, which would make it the world's first federally regulated major marijuana sector. That means companies based out of Canada and capable of scaling up quickly to meet the demands of the market could become the world's weed 'multinationals', rivaling the big U.S. and European tobacco firms.
One company that is ready to take full advantage of Canada's demand for marijuana is Cannabis Wheaton. The company's novel approach to demand challenges takes a leaf out of Netflix's book: 'streaming weed', by which the company offers a life-line to growers in exchange for royalties.
This financing model is similar to that used in the mining industry, and it should provide Cannabis Wheaton with the flexibility to scale up supply quickly, in order to meet Canada's weed demand, without undertaking the risks of putting all of its money into one supply source.
CBW already has 15 partners, with 17 facilities and the potential to achieve 1.4 million effective square feet of productive acreage. In exchange for the construction capital provided to its partners, CBW gets a minority equity interest and a percentage of such partners cannabis production. CBW has established relationships with 39 clinics already and has access to 30,000 registered medical marijuana patients, a fifth of Canada's existing legal market.
Cannabis Wheaton is the only company on the legal-distribution finance source track, and its game-plan looks solid and relatively low-risk. If one producer falls through, say if the crop goes bad or the regulators find a problem, CBW can quickly pivot to another.
More importantly, this structure allows the company to take profits and quickly re-invest them into new sources of supply: the potential for a quick scale-up when pot becomes fully legal in Canada next year is immense, particularly when you factor in CBW's expected low operational costs.
Demand is expected to increase rapidly and access to capital is going to be a major constraint for smaller firms looking to fill the market's need for production quickly. CBW's royalty-model should allow it to profit quickly from expanded production, allowing it to pump fresh capital into new production, assisting growers who would otherwise only be able to scale up slowly.
Recent catalysts for the company's future prospects include a $15 million purchase of shares in ABcann Global Corporation in August, which forms part of a larger investment into ABcann that will add 50,000 square feet of acreage to ABcann's cultivation facility. Another $15 million purchase of ABcann shares is scheduled for next year, with half of the production revenues of such 50,000 square foot expansion going to CBW.
ABcann could become a major supplier to CBW in the future, as it brings this new capacity on-line. With a planned for margin of $4.5/gram, that could translate into a 70 percent internal rate of return.
The company's leadership, including CEO Chuck Rifici, has a strong track-record in bringing marijuana ventures to profitability. Rifici led Canopy Growth Corp. to its public offering in April 2014, building the company to a market cap of $1 billion, and he looks poised to duplicate that success with Cannabis Wheaton. There is strong political support for CBW's model, which will help with a smoother transition for Canada's cannabis sector as it goes legal next year.
With support like this, a strong model and high potential for immense growth once legalization takes off, Cannabis Wheaton is definitely a cannabis stock to watch.
Altria Group (NYSE: MO)
The largest cigarette seller with over half the market in the United States, Altria could be poised to enter the weed business, as cigarette sales decline and medical marijuana becomes more acceptable and tightly regulated. Like Philip Morris, the company is wary to go all-in when the regulatory environment within the U.S. remains so uncertain.
The company is a true blue-chip, a reliable source of dividends and a strong earner. Since last year, Altria has been watching emerging marijuana legislation very closely, as it invests heavily in vape technology. Speculation that the tobacco giant was getting into the weed game began in 2015, as the company's cigarette sales were in decline, though revenue was sustained by price hikes.
So far, there's no hard info on the company investing in marijuana start-ups or technology, the way Philip Morris has done. Yet given its size and interest in developing new products, it's entirely possible Altria may develop an interest in cannabis.
Altria is the best-equipped company to take advantage of marijuana's increasing legality. It owns a number of highly-profitable cigarette brands and enjoys very low capex requirements each year, due to the scale of its enterprise. Its financial resources are massive, and presently spends almost nothing on advertising, as tobacco products are restricted by law from most media.
In 2015, Altria generated $5.8 billion in operating cash flow and just $229 million in capex, translating into free cash flow of $5.6 billion. With such immense profits year on year, the company probably has more capital than any other potential player in the cannabis market and could potentially dominate as a marketer and distributor.
In light of future declining cigarette sales, it seems natural for Altria to broaden its activities into other, similar sectors. Altria getting into the cannabis game seems like a no-brainer.
Insys Therapeutics (NASDAQ: INSY)
Along with Big Tobacco, another sector worth looking into for emerging marijuana-related stocks is pharmaceuticals. Weed's big break came in the medical sector, as marijuana emerged as a popular and effective treatment for a host of ailments, from pain relief to depression, anxiety and glaucoma.
While not a marijuana stock per se, Insys Therapeutics is on the cutting edge of the emerging trends in medical marijuana research and development. The company has two drugs approved by the US FDA, named Subsys and Syndros.
While the first drug is a high earner for the company, it has little to do with cannabis. But Syndros is a pharmaceutical variety of THC (tetrahydrocannabinol) the active ingredient in marijuana. In March it cleared a federal regulatory hurdle in the U.S. and could likely launch later this year.
The company has been quite successful marketing these products, and looks set to invest some of its significant cash flow (it had $236.7 million in-hand at the end of 2016) into new research and development of cannabis-related drugs.
A cloud hangs over the company, in that Subsys has been challenged by regulators and tied up with litigation. With sales of that drug falling, Insys has shifted to research and development.
Its share price has plummeted in recent years, but new cannabis-based sprays currently in development could bring the company back from its slump. One drug, a cannabidiol intended to treat childhood epilepsy, shows particular promise.
With strong activity in its development pipeline, Insys could be a strong performer in the field of medical cannabis-based products and a good earner for those investors able to take advantage of the current low share price.
GW Pharmaceuticals (NASDAQ: GWPH)
Towering above all other marijuana stocks with a $3 billion valuation and a strong earnings record, GW Pharmaceuticals is the biggest name in cannabis. A drug developer that specializes in cannabinoids, the company has its hands in a number of new developing products, including drugs aimed at epilepsy, infantile spasms, autism and schizophrenia.
One drug in particular should get cannabis investors excited. Epidiolex is an experimental product used in the treatment of childhood epilepsy. The drug has over-performed in clinical trials, with a reduction in seizures of 50 percent. With a success rate this strong, it seems possible that Epidiolex could see strong demand and even better sales once it's introduced to the market.
While firms like Cannabis Wheaton look set to take Canada by storm, GW Pharma is best positioned to take advantage of the growing boom in medical marijuana and cannabis-related products inside the United States. It could see some competition from Insys, which as noted before is developing its own epilepsy treatment utilizing cannabidiol. There may not be room for two products boasting such similar pedigrees.
GW Pharma has an advantage in that it has a strong presence in the United Kingdom. The company plans to invest £50 million and hire 70 new staff for its Britain-based facilities. The company is well-positioned to take advantage of greater interest in medical-marijuana and cannabis-based products on both sides of the Atlantic.
Other companies to keep a close eye on in the space:
Teva Pharmaceuticals (NYSE:TEVA) is an Israel-based company which develops, manufactures, and markets a variety of specialty medications. The company is the world's largest generic drug maker and is represented in markets across the planet. Teva has recently joined the cannabis race with a product designed to treat pain using cannabis administered through an inhaler.
Teva's substantial market share and motivation to grow, in addition to its innovative drive make it a very appealing stock for investors. The company is one of the few on this list which pay out dividends to investors, and with its incredible marketing strategy, it offers great value to those who hold shares.
MedReleaf Corp (OTC: MEDFF) (TSX: LEAF.TO): As a licensed producer of cannabis-based pharmaceutical products, MedReleaf Corp has a head start on the coming boom in Canada. Early July has seen a bounce in the stock price, and investors may look to ride it upward from here. Med Releaf could become Canada's second biggest medical marijuana company after Canopy Growth Cooperation as many analysts expect the 'legal weed' industry to grow 25% on an annual basis over the next 10 years.
MedReleaf has seen its share price fall since June, but has steadied out in recent months and could be poised for gains as the expected legalization of recreational marijuana materializes.
By. Charles Kennedy
**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
FORWARD-LOOKING STATEMENT. Statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense. Forward looking statements in this article include that new cannabis legalizing legislation will create an $8-billion-dollar industry; that there will likely be a supply shortage; that this industry will be $25 billion annually in the US; that Cannabis Wheaton's business model reduces risk for investors; the ability to generate revenue or take production through the streaming agreements. Forward-looking information is based on the opinions and estimates of Cannabis Wheaton at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Forward looking statements involve known and unknown risks and uncertainties which may not prove to be accurate. Actual results and outcomes may differ materially from what is expressed or forecasted in these forward-looking statements. Matters that may affect the outcome of these forward looking statements include that markets may not materialize as expected; marijuana may not turn out to have as large a market as thought or be as lucrative as thought as a result of competition or other factors; Cannabis Wheaton may not be able to diversify or scale up as thought because of potential lack of capital, lack of facilities, regulatory compliance requirements in Canada or outside of Canada or lack of suitable employees or contacts; partners of Cannabis Wheaton may not be granted licenses or additional capacity under existing licenses for them to grow for the cannabis market; and other risks affecting Cannabis Wheaton in particular and the cannabis industry generally. The forward-looking statements in this document are made as of the date hereof and the Company disclaims any intent or obligation to update such forward-looking statements except as required by applicable securities laws.
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Safehaven.com, and their owners, managers, employees, and assigns (collectively "the Company") has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by Cannabis Wheaton one hundred and fifty four thousand US dollars for this article and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically:
This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated by Cannabis Wheaton Income Corp. to conduct public awareness advertising and marketing for [TSX:CBW.V]. Safehaven.com receives financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated public awareness efforts. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of public awareness marketing, which often end as soon as the public awareness marketing ceases. The public awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, The Company often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications.
NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LEGAL ADVISORY. Investing in companies associated with the cannabis industry may be illegal in the jurisdiction where a reader resides. Before investing in any public company involved in the cannabis industry, potential investors should check with their legal advisor as to whether an investment will breach local law.
DISCLAIMER: Safehaven.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with Safehaven.com or any company mentioned herein. The commentary, views and opinions expressed in this release by Safehaven.com are solely those of Safehaven.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.